Abaza Y,Kantarjian H,Garcia-Manero G,Estey E,Borthakur G,Jabbour E,Faderl S,O'Brien S,Wierda W,Pierce S W .2017 .Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 129(10) : 1275-1283.
Ader D,Durrani M,Blazar E .2019 .Disseminated intravascular coagulation with purpura fulminans presentation of acute promyelocytic leukemia. CPCEM., 3(4) : 446.
Barragán E,Montesinos P,Camos M,González M,Calasanz MJ,Román-Gómez J,Gómez-Casares MT,Ayala R,López J,Fuster Ó .2011 .Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica, 96(10) : 1470-1477.
Cicconi L,Platzbecker U,Avvisati G,Paoloni F,Thiede C,Vignetti M,Fazi P,Ferrara F,Divona M,Albano F M .2019 .Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia, 34(3) : 914-918.
Creutzig U,Zimmermann M,Bourquin J-P,Dworzak MN,Fleischhack G,Graf N,Klingebiel T,Kremens B,Lehrnbecher T .2013 .Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. , 122(1) : 37-43.
Ghavamzadeh A,Alimoghaddam K,Rostami S,Ghaffari SH,Jahani M,Iravani M,Mousavi SA,Bahar B,Jalili M .2011 .Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clinic Oncol, 29(20) : 2753-2757.
Iland HJ,Bradstock K,Supple SG,Catalano A,Collins M,Hertzberg M,Browett P,Grigg A,Firkin F,Hugman A .2012 .All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 120(8) : 1570-1580.
Kwaan HC,Weiss I,Tallman MS .2019 .The role of abnormal hemostasis and fibrinolysis in morbidity and mortality of acute promyelocytic leukemia. Semin, 45(6) : 612-621.
Lee J-H,Kim H,Joo Y-D and H .2017 .Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia. J. Clin. Oncol., 35(24) : 2754-2763.
Lo-Coco F,Avvisati G,Vignetti M,Thiede C,Orlando SM,Iacobelli S,Ferrara F,Fazi P,Cicconi L,Di Bona E .2013 .Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med, 369 : 111-121.
Lou Y,Qian W,Meng H,Mai W,Tong H,Tong Y,Huang J,Jin J .2013 .High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leukemia Research, 37(1) : 37-42.
Ma Y,Liu L,Jin J,Lou Y .2016 .All-trans retinoic acid plus arsenic trioxide versus all-trans retinoic acid plus chemotherapy for newly diagnosed acute promyelocytic leukemia: A meta-analysis. PloS one, 11(7) : e0158760.
Noguera NI,Catalano G,Banella C,Divona M,Faraoni I,Ottone T,Arcese W,Voso MT .2019 .Acute promyelocytic leukemia: Update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies. Cancers, 11(10) : 1591.
Ohtake S,Miyawaki S,Fujita H,Kiyoi H,Shinagawa K,Usui N,Okumura H,Miyamura K,Nakaseko C,Miyazaki Y C .2011 .Randomized study of induction therapy comparing standard-dose idarubicin with highdose daunorubicin in adult patients with previously untreated acute myeloid leukemia: The JALSG AML201 Study. , 117(8) : 2358-2365.
Orfali N,O'Donovan TR,Cahill MR,Benjamin D,Nanus DM,McKenna SL,Gudas LJ,Mongan NP .2020 .All‐trans retinoic acid (ATRA)‐induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL). Eur. J. Haematol., 104(3) : 236-250.
Park JH,Qiao B,Panageas KS,Schymura MJ,Jurcic JG,Rosenblat TL,Altman JK,Douer D,Rowe JM,Tallman MS JM .2011 .Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood, 118(5) : 1248-1254.
Ravandi F,Estey E,Jones D,Faderl S,Kantarjian H S .2009 .Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J. Clin. Oncol., 27(4) : 504-510.
Sanz MA,Fenaux P,Tallman MS,Estey EH,Löwenberg B,Naoe T,Lengfelder E,Döhner H,Burnett AK,Chen S-J .2019 .Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. , 133(15) : 1630-1643.
Sanz MA,Montesinos P .2020 .Advances in the management of coagulopathy in acute promyelocytic leukemia. Thromb. Res, 191 : S63-S67.
Sanz MA,Montesinos P,Kim HT,Ruiz-Argüelles GJ,Undurraga MS,Uriarte MR,Martínez L,Jacomo RH,Gutiérrez-Aguirre H,Melo RAM H .2015 .All-trans retinoic acid with daunorubicin or idarubicin for riskadapted treatment of acute promyelocytic leukaemia: A matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. , 94(8) : 1347-1356.
Tomita A,Kiyoi H,Naoe T H .2013 .Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As 2 O 3) in acute promyelocytic leukemia. Int. J. Hematol., 97(6) : 717-725.
Zhao J,Liang J-W,Xue H-L,Shen S-H,Chen J,Tang YJ,Yu L-S,Liang H-H J-Y .2019 .The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia. Leukemia, 33(6) : 1387-1399.